Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

1

Patients with hematological malignancies have a higher Covid-19 mortality rate of 33–37% compared to the general population.
2

A study evaluated the immune response to the Comirnaty vaccine in patients with hematological malignancies post-autologous stem cell transplantation.
3

87% of patients developed a humoral immune response, with a median antibody titer of 747 BAU/ml after vaccination.
4

Not having autologous stem cell transplantation as the last treatment and being on active therapy were linked to vaccination failure.
5

Cell-mediated immunity analysis showed lower spike-specific T-cell responses in seronegative patients compared to seropositive patients.

Bone Marrow Transplantation

by Marco Salvini, Fabrizio Maggi, Camilla Damonte, Lorenzo Mortara, Antonino Bruno, Barbara Mora, Marco Brociner, Roberta Mattarucchi, Alessia Ingrassia, Davide Sirocchi, Benedetta Bianchi, Stefania Agnoli, Matteo Gallazzi, Michele Merli, Andrea Ferrario, Raffaella Bombelli, Daniela Barraco, Andreina Baj, Lorenza Bertù, Paolo A. Grossi, Francesco Passamonti
October 11, 2021

1